Company intelligence / Profile preview
ARS Pharmaceuticals
San Diego, California, United Statesars-pharma.com ↗
- Ownership
- Public · SPRY
- Employees
- ~50
- Development stage
- Commercial
01
Overview
ARS Pharmaceuticals has developed neffy® (epinephrine nasal spray), the first and only FDA-approved needle-free epinephrine product for emergency treatment of allergic reactions including anaphylaxis. Based on review timelines, product availability of neffy 1 mg is expected by the end of May 2025.
- Therapeutic areas
- ImmunologyDermatology
- Modalities
- Small moleculesHormones
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
ALK-Abelló A/SNeurelis (Intravail® licensee relationship)
04
Financials
- Market cap
- $535.2M
- Total revenue
- $33.7M
- Enterprise value
- $563M
Beyond the preview
Go deeper on ARS Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARS Pharmaceuticals.